Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Bevacizumab> ?p ?o. }
Showing items 1 to 96 of
96
with 100 items per page.
- Bevacizumab abstract "Bevacizumab (pronounced /bev-a-Sizz-you-mab/, trade name Avastin, Genentech/Roche) is an angiogenesis inhibitor, as a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney and ovarian.Bevacizumab is a humanized monoclonal antibody that produces angiogenesis inhibition by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available, angiogenesis inhibitor in the United States.[citation needed]Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) for certain metastatic cancers. It received its first approval in 2004, for combination use with standard chemotherapy for metastatic colon cancer. It has since been approved for use in certain lung cancers, renal cancers, ovarian cancers, breast cancers and glioblastoma multiforme of the brain.The first indication approval for metastatic colorectal cancers saw huge uptake of this pioneer of anti-VEGF therapy which till today remains as a cancer type that responds well to Avastin. The overwhelming data of trials for usage of Avastin with a fluoropyrimidine demonstrates its efficacy and safety; which continually extends survival for this group of patients. The reason for its overall success is attributed to the fact that its parent company, Roche, allows their scientists to have one fifth of their working time to spend on a research area of their own interest. This led one of their scientists, Napoleone Ferrara, to chance upon and develop this novel therapy that has since extended the lives of thousands of patients. 27 February 2004.At one point bevacizumab was approved for breast cancer by the FDA, but the approval was revoked on 18 November 2011. The approval for breast cancer was revoked because, although there was evidence that it slowed progression of metastatic breast cancer, there was no evidence that it extended life or improved quality of life, and it caused adverse effects including severe high blood pressure and hemorrhaging. In 2008, the FDA gave bevacizumab provisional approval for metastatic breast cancer, subject to further studies. The FDA's advisory panel had recommended against approval. In July 2010, after new studies failed to show a significant benefit, the FDA's advisory panel recommended against the indication for advanced breast cancer. Genentech requested a hearing, which was granted in June 2011. The FDA ruled to withdraw the breast cancer indication in November 2011. FDA approval is required for Genentech to market a drug for that indication. Doctors may sometimes prescribe it for that indication, although insurance companies are less likely to pay for it. The drug remains approved for breast cancer use in other countries including Australia.Clinical trials are underway for many other indications including ovarian cancer, pediatric osteosarcoma, and certain non-malignant eye diseases. In the curative setting (adjuvant therapy), clinical studies are underway in breast cancer and lung cancer.".
- Bevacizumab atcPrefix "L01".
- Bevacizumab atcSuffix "XC07".
- Bevacizumab bioavailability "100.0".
- Bevacizumab casNumber "216974-75-3".
- Bevacizumab drugbank "DB00112".
- Bevacizumab fdaUniiCode "2S9ZZM9Q9V".
- Bevacizumab wikiPageExternalLink nccn-guidelines-for-breast-cancer-updated-bevacizumab-recommendation-affirmed.html.
- Bevacizumab wikiPageExternalLink dpdirect.jsp?name=Bevacizumab.
- Bevacizumab wikiPageExternalLink articles.php?tag=Avastin.
- Bevacizumab wikiPageExternalLink catt-study-update-3-avastin-vs-lucentis.html.
- Bevacizumab wikiPageExternalLink S1526-8209(11)70536-5.
- Bevacizumab wikiPageExternalLink Page1.html.
- Bevacizumab wikiPageExternalLink www.avastin-info.com.
- Bevacizumab wikiPageExternalLink www.avastin.com.
- Bevacizumab wikiPageExternalLink drugdictionary.aspx?CdrID=43234.
- Bevacizumab wikiPageExternalLink bevacizumab.
- Bevacizumab wikiPageExternalLink ?q=AVASTIN.
- Bevacizumab wikiPageExternalLink 15drug.html?ex=1297659600&en=62aabaec5acffa8c&ei=5090&partner=rssuserland&emc=rss.
- Bevacizumab wikiPageID "1527537".
- Bevacizumab wikiPageRevisionID "605408149".
- Bevacizumab atcPrefix "L01".
- Bevacizumab atcSuffix "XC07".
- Bevacizumab bioavailability "100.0".
- Bevacizumab c "6638".
- Bevacizumab casNumber "216974".
- Bevacizumab chembl "1201583".
- Bevacizumab chemspiderid "NA".
- Bevacizumab drugbank "DB00112".
- Bevacizumab eliminationHalfLife "1728000.0".
- Bevacizumab h "10160".
- Bevacizumab hasPhotoCollection Bevacizumab.
- Bevacizumab kegg "D06409".
- Bevacizumab legalStatus "Rx-only".
- Bevacizumab licenceEu "Avastin".
- Bevacizumab licenceUs "Bevacizumab".
- Bevacizumab mabType "mab".
- Bevacizumab molecularWeight "approx. 149 kDa".
- Bevacizumab n "1720".
- Bevacizumab o "2108".
- Bevacizumab pregnancyUs "C".
- Bevacizumab routesOfAdministration Intravenous_therapy.
- Bevacizumab s "44".
- Bevacizumab source "zu/o".
- Bevacizumab target Vascular_endothelial_growth_factor_A.
- Bevacizumab tradename "Avastin".
- Bevacizumab type "mab".
- Bevacizumab unii "2".
- Bevacizumab verifiedfields "changed".
- Bevacizumab verifiedrevid "477165031".
- Bevacizumab subject Category:Angiogenesis_inhibitors.
- Bevacizumab subject Category:Monoclonal_antibodies_for_tumors.
- Bevacizumab subject Category:Ophthalmology_drugs.
- Bevacizumab subject Category:Orphan_drugs.
- Bevacizumab type Agent114778436.
- Bevacizumab type AngiogenesisInhibitor102711422.
- Bevacizumab type AngiogenesisInhibitors.
- Bevacizumab type CausalAgent100007347.
- Bevacizumab type Drug103247620.
- Bevacizumab type Matter100020827.
- Bevacizumab type Medicine103740161.
- Bevacizumab type OrphanDrugs.
- Bevacizumab type PhysicalEntity100001930.
- Bevacizumab type Substance100020090.
- Bevacizumab type Drug.
- Bevacizumab type DrugProduct.
- Bevacizumab type FunctionalSubstance.
- Bevacizumab comment "Bevacizumab (pronounced /bev-a-Sizz-you-mab/, trade name Avastin, Genentech/Roche) is an angiogenesis inhibitor, as a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney and ovarian.Bevacizumab is a humanized monoclonal antibody that produces angiogenesis inhibition by inhibiting vascular endothelial growth factor A (VEGF-A).".
- Bevacizumab label "Bevacizumab".
- Bevacizumab label "Bevacizumab".
- Bevacizumab label "Bevacizumab".
- Bevacizumab label "Bevacizumab".
- Bevacizumab label "Bevacizumab".
- Bevacizumab label "Bevacizumab".
- Bevacizumab label "Bewacizumab".
- Bevacizumab label "Bévacizumab".
- Bevacizumab label "Бевацизумаб".
- Bevacizumab label "بيفاسيزوماب".
- Bevacizumab label "ベバシズマブ".
- Bevacizumab label "安维汀".
- Bevacizumab sameAs Bevacizumab.
- Bevacizumab sameAs Bevacizumab.
- Bevacizumab sameAs Bévacizumab.
- Bevacizumab sameAs Bevacizumab.
- Bevacizumab sameAs ベバシズマブ.
- Bevacizumab sameAs Bevacizumab.
- Bevacizumab sameAs Bewacizumab.
- Bevacizumab sameAs Bevacizumab.
- Bevacizumab sameAs m.0584_3.
- Bevacizumab sameAs Q413299.
- Bevacizumab sameAs Q413299.
- Bevacizumab sameAs bevacizumab.
- Bevacizumab sameAs DB00112.
- Bevacizumab sameAs Bevacizumab.
- Bevacizumab wasDerivedFrom Bevacizumab?oldid=605408149.
- Bevacizumab isPrimaryTopicOf Bevacizumab.